

- tumors and a mitomycin C-resistant tumor in vitro and in vivo 89
- Twelves C → Dunkelman H
- Twelves CJ, Ash CM, Miles DW, Thomas DGT, Souhami RL: Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma 481
- Valdivieso M → Chabot GG
- Valeriotte F → Brodfuehrer J
- van der Vijgh WJf → Leeuwenkamp OR
- van Tellingen O → Deurloo MJM
- Varnavas A → Sava G
- Verma S → Stewart DJ
- Venitt S → Brookes P
- Villacorte DG → Newman EM
- Vindelov L → Jensen PB
- Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J, Cooper MR, Coughlin KM, Green MR: Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B 239
- Voth E → Rauschecker HF
- Vukas D → Kolarić K
- Wallis J → Jackson GH
- Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD, Schold SC Jr: Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts 278
- Watanabe M → Nakajima T
- Watson JV → Smith PJ
- Waud WR, Harrison SD Jr, Gilbert KS, Laster R Jr, Griswold DP Jr: Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia 456
- Whitehouse E → Robbins MEC
- Wilkinson P → Logue J
- Willemze R → Colly LP
- Willenbrock C → Rauschecker HF
- Williams CJ → Coleman RE
- Wiltshaw E → Coleman RE
- Wold H → Gandara DR
- Wyrick SD → Carfagna PF
- Xu Y-J, Li D-D, Zhen Y-S: Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells 41
- Yamada N → Nakajima T
- Yamamoto M → Saito H
- Yokoyama K → Nakajima T
- Yurkow EJ, Laskin JD: Mechanism of action of psoralens: isobologram analysis reveals that ultraviolet light potentiation of psoralen action is not additive but synergistic 315
- Zeller WJ → Frühauf S
- Zhen Y-S → Xu Y-J
- Zorzet S → Sava G

Indexed in *Current Contents*

Subject index of volume 27

- Adenocarcinoma 487
- Adriamycin 413
- Advanced breast cancer 101, 394, 477
- Advanced human breast cancer 326
- Advanced lung cancer 229
- Advanced non-small cell lung cancer 243
- Alkylating drugs 278
- Alveolitis 168
- Aminoglutethimide 101, 451
- Amsacrine 397
- Animal scale-up 20
- Anthracycline metabolism 147
- Antiemetic effect 472
- Antiestrogens 8
- Antimetastatic compound 423
- Antitumor activity 89, 194, 263
- Antitumor agent 295
- Antitumor biotic 41
- Antitumor effects 8, 429
- Ara-C 151
- Aromatase inhibitor 367
- Bioavailability 308
- Biochemical modulation 60
- Biodistribution 13
- Biotransformation 335
- Bleomycin 484
- Bone marrow transplantation 361
- Brain 1
- Breast cancer 79, 367, 409, 451
- Busulfan 226
- Carboplatin 229, 239, 409, 481, 484
- Carboplatin-based chemotherapy 234
- Carboplatin/etoposide 389
- Carcinoma of the cervix 52
- Celiptium-induced nephrotoxicity 178
- Cell-cycle progression 464
- Cell density 417
- Cell differentiation 171
- Cell kinetics 121
- Cellular pharmacokinetics 320, 417
- Cerebellar toxicity 76
- Cervical carcinoma 484
- Chemotherapy 52, 72, 94, 385, 394, 413, 477
- Children 60, 164, 397
- 2-Chloro-2',3'-dideoxyadenosine 285
- Cimetidine 125
- cis-Dichloro-bis-isopropylamine platinum (II) 248
- Cisplatin 33, 52, 55, 111, 121, 131, 135, 211, 251, 347, 417, 464, 472
- Cisplatin-resistant P388 leukemia 456
- c-Myc expression 171
- Combination chemotherapy 81, 131, 251
- Combined modality treatment 94
- Comparative disposition 106
- Comparative effects 47
- Cross-resistance 456
- Cyclophosphamide 1, 125, 440
- Cytarabine 33, 60, 76, 151
- Cytosine arabinoside 141
- Cytotoxicity 41, 342, 440
- Dacarbazine 81
- Decarbazine pharmacokinetics 157
- 1,2-diaminocyclohexaneplatinum(IV) 335
- Diffusorodeoxycytidine 2' 258
- Distribution 347
- DNA binding 248
- DNA polymerase 199
- Doxorubicin 47, 219
- Doxorubicinol 219
- Drug interaction 101
- Drug resistance 151
- Ecomustine 295
- ELISA 115
- Endocrinology 367
- Epidoxorubicin 4' 47
- Epipodophyllotoxin 194
- Epirubicin glucuronide 147
- Etoposide 115
- Feasibility 490
- Flavone acetic acid 27
- Flow-through system 320
- Fluorouracil 5- 79, 131, 320, 477
- Flutamide 401
- Fotemustine 81
- Fotemustine [¹⁴C]- 106
- Galactosidase 115
- Gastrointestinal lymphoma 385
- Gemcitabine 258
- Glioma 278
- Head and neck carcinoma 464
- Hepatic enzyme 226
- Hepatocytes 320
- Hepatoma BEL-7402 cells 41
- High-dose cisplatin 243
- High-dose epirubicin 394
- High-grade glioma 481
- Histidine 271

- HL-60 cells 171
 HO-221 199
 Hodgkin's disease 161
 Hoechst 33342 445
 Homocysteine 331
 HPLC 295
 Human tumour cells 445
 4-Hydroxyandrostenedione 67
 7-Hydroxymethotrexate 164
 Hydroxyurea 33, 168
- Idarubicin 308
 Ifosfamide 52, 251
 Imidazotetrazine 342
 Immunodeficiency virus-1 agent 285
 Inflammatory carcinoma 94
 Infusion 472
 Inoculum effect 417
 Interleukin-2 157
 Intraperitoneal chemotherapy 121
 Intrathecal chemotherapy 329
 Intratumoural drug administration 347
 Intratumoural slow release 135
 In vitro culture conditions 354
 Iproplatin 248, 481
 Isobologram analysis 315
- Kinetics 379
- Leakage 379
 Leucovorin 131
 Leukemia 141
 Limb 379
 Lipid peroxidation 178
 Liposomal doxorubicin 13
 Liposomes 429
 Lung 487
 Lymphoblastic leukemia 164
 Lymphocytes 413
- Mafosphamide 440
 Malignant melanoma 81
 Malignant mesothelioma 239
 MDL 72222 472
 Mechanism of action 199
 Medroxyprogesterone 101, 271
 Melanoma 157, 379
 Melfalan 379
 Mesna 111
 Metabolism 141, 342
 Metal complexes 301
- Methotrexate 60, 484
 Methotrexate toxicity 331
 Mice 106
 Mitomycin C 79, 243, 290
 Mitomycin C-resistant tumor 89
 Mitoxantrone 429, 477
 Monomethyl derivative 423
 Mononuclear cells 258
 Multidrug resistance 290, 445
 Myelocytic leukemia 151
 Myeloid leukemia 168
 Myelosuppression 13
 Myelotoxicity 226
 Mytomycin derivative 89
- Nafazatrom 326
 Nephrectomy 211
 Neurological deficit 329
 Neurotoxicity 226
 Neutropenia 253
 Nigericin 440
 Nimustine hydrochloride 20
 Nonlymphocytic leukemia 397
 Non-small-cell lung cancer 72, 251
- Ovarian carcinoma 389
 Ovarian tumors 301
- P388 cells 187
 Perfusion 279
 Pharmacodynamics 67, 147, 263, 373
 Pharmacokinetics 1, 55, 67, 205, 219, 234, 367, 373, 397, 401, 406, 429, 451
 Pharmacology 308, 361
 Pharmacology of metabolites 8
 Phase II study 239
 Phase I study 131, 229, 258
 Phosphoramidate mustard 1
 Pilot study 389
 Plasma 1
 Plasma concentration 20
 Platinum 301
 Platinum analogs 263
 Platinum pharmacology 72
 Porfiromycin 187
 Preclinical 89, 194
 Preclinical study 361
 Prednimustine 477
 Protecting agents 111
 Protein binding 27
 Protein binding ACNU 20
- Psoralens 315
 Purine analogs 171
- Rabbits 125
 Radiosensitiser 55
 Reaction kinetics 111
 Recombinant interferon alpha-C 406
 Refractory testicular cancer 85
 Renal cortex 178
 Renal function 211
 Renal insufficiency 76, 234
 rG-CSF 253
 Rhodamine 123 205
 Rodent mammary tumours 271
 Ruthenium 301
- Salvage chemotherapy 85
 Salvage chemotherapy 161
 Slow-release 347
 Small-cell lung cancer 490
 Stability 295
 Stability of etoposide 354
 Sustained release 401
 Synergism 315
- Teniposide 85, 397, 487
 TEPA 373
 Tetrachloro (d,ltrans)1,2-diaminocyclohexaneplatinum (IV) 335
 Tetraplatin 335
 Thiopurines 278
 Thiosulfate 111
 thio-TEPA 373
 Titanium 301
 Toremifene 8
 Toxicity 135, 335, 429
 Triazenes 342
 Triglycidylurazol 1,2,4- 361
 Trisomy 21 331
 Tumor 1, 106
 Tumor model 121
- Urogenital cancer 253
 UV 315
- Verapamil 413
 Vinblastine 251
 Vincristine 484
 VM-26 194
 VP-16 194
- Xenografts 278, 464

